Loading…
Based on limited metadata, GlutaGenic received an FDA Warning Letter on May 6, 2020, regarding drug products. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The warning was issued by the FDA's drug regulatory division, though the specific issuing office is not identified in this metadata. To understand the specific compliance issues cited, review of the complete Warning Letter would be necessary.